Entirely Noninvasive Outcome Prediction in Central Nervous System Lymphomas Using Circulating Tumor DNA

Scientists applied ultrasensitive circulating tumor DNA sequencing to 146 plasma and cerebrospinal fluid samples from 67 patients, with the aim of developing an entirely noninvasive dynamic risk model considering clinical and molecular features of central nervous system lymphoma.